ORIGINAL RESEARCH article
Front. Public Health
Sec. Substance Use Disorders and Behavioral Addictions
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1630412
Sex Differences in Drug-Induced Osteoporosis: A Pharmacovigilance Study Based on the FAERS Database
Provisionally accepted
- Gansu University of Chinese Medicine, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Osteoporosis is a prevalent condition globally, often linked to a significant risk of fractures. Drug-induced osteoporosis (DIOP) is an increasingly recognized adverse effect of various medications, but the sex-specific risks and time-to-onset patterns remain inadequately understood. Addressing these gaps in knowledge is critical to improving patient safety and pharmacovigilance. Objective: This study aimed to explore sex-related differences in DIOP, identify high-risk medications, and assess the onset patterns of osteoporosis-related adverse events by analyzing data from the FDA Adverse Event Reporting System (FAERS) and validating the findings using the Canada Vigilance Adverse Reaction Online Database (Canada Vigilance ADR). Methods: We analyzed adverse event reports from the FAERS database covering the period from Q1 2004 to Q4 2024. Drugs were standardized using the RxNorm drug terminology system, and adverse events were matched to MedDRA 27.1. Disproportionality analysis was conducted using Reporting Odds Ratio (ROR), Multi-item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN) methods. To validate our findings, we performed external validation using the Canada Vigilance ADR database. Stratified analyses by sex were performed to assess differences in drug-osteoporosis associations. Results: A total of 236,928 osteoporosis-related reports were identified, with 64.6% of the reports coming from females. We identified 68 drugs associated with DIOP, including 15 male-specific and 26 female-specific potential risk drugs. Notable drugs such as TENOFOVIR DISOPROXIL and ESOMEPRAZOLE were linked to both sexes. Drugs like UPADACITINIB exhibited early-onset failure patterns, while others like TENOFOVIR demonstrated cumulative risk patterns over prolonged use. External validation with the Canada Vigilance ADR confirmed 32 drugs with potential osteoporosis risks. Conclusions: This study highlights important sex-specific differences in the risk of drug-induced osteoporosis and underscores the need for targeted pharmacovigilance strategies. The findings contribute to a more personalized approach to drug safety, promoting more informed decision-making regarding medication use in osteoporosis-prone populations.
Keywords: Drug-induced osteoporosis, FAERS, Sex-specific risk, mGPS, BCPNN, Time-to-onset analysis, Pharmacovigilance
Received: 17 May 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Liu, Song, Liu, 宋 and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Min Song, Gansu University of Chinese Medicine, Lanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.